Okyanos is in the Bahamas quite frankly Cytori is not gaining enough recognition as of yet, nor does marc hedrick speak much about them , look at minutes from last CC and I doubt there was even a mention. We don't know what they may be generating from purchase of consumables but can't be much. Hopefully results will be positive as they are doing many types of procedures. Growing like crazy is a bit of over exhuberance.
Munger, why don't you listen to what marc said and then you will have your answer. Cytori will place the machines and the consumables and they will sell the end product. The end product will the be reimbursed by insurance and the FDA has the control over the use of the cells as the software contained in Cellution 2 machine tracks all of this. The machines will also be used for other treatments as approvals are granted. the idea is for the FDA to eliminate usage that is going on by all kinds of doctors for unauthorized treatments. Again this was worked out between FDA and Cytori. In addition the govt does not have to outlaw cash unless they actually need cells to treat burns in the case of BARDA ,however, the machines ould be used lets say for an approved treatment for Sceloderma if that is approved, cardiac if approved, hamstring etc. if approved. outside of the US is a different store and razor razor blade model will work as it does at Okyanos for instance. Don't be obstinate just listen to the call from year end 2014 and you will understand.
I don't doubt Mungers smarts, you guys jusr not willing to listen to what your own CEO has told you about Cytori's business model. This is not my model it is his so listen read on your own and do your own DD. This was discussed in detail months ago and is not new news. In addition it is not your place to tell me what to think or how to express myself. Just put me on ignore and you no longer have to deal with either. Now go ask Fas to explain it to you, he will. or grow up and do your own DD. Like your nose the info is in front of your face. It is also not a negative thing that the govt will not be buying machines, but will be buying the finished product as well as it is not a bad thing if the FDA chooses to finally enforce rules governing use of stem cells. Once you clear the war out of your ears you may even grasp the concept. Now go on a buy some more shares, Marc surely has instilled the confidence in you that know is a wise time to do so and perhaps your buddy Munger who surely does not need you to defend his thoughts might as well too. GLTY and put your ignore feature to good use. I sure have on this MB.
MC your e mail is not relevant as you are under a false assumption and are not understanding of the facts. Go back and listen to the call before the last one where Marc specifically answers the question and addresses the change in marketing strategy due to guidance from the FDA.
Just listen to the conference call before this last one and you can become a bit more familiar with the company you are invested in.
All the information you need is available, this is not new news.
MC, clearly you are out of the loop. The razor,razor blade model is dead. The FDA has directed and the government has informed Cytori,that they are not going to purchase machines or disposables. They will buy the finished product the stem cells. Cytori will be responsible for the placement and costs of the machines. Outside the US machines can be purchased and used for treatments but in the US the FDA wants to control specific use of cells and the soft wear in the machines can track patient and application of stem cells. The bigger problem is that the machine is delayed again and Hedrik has absolutely no idea when it will be completed as he just skipped over this in the conference call hoping that nobody would notice. Of course this has been the strategy for years hoping that shareholders would not hold management accountable for companies failures and we have not. Only class action suit will allow management and BOD to be deposed under oath
and then we can get to the truth. Unfortunately a class action will not recoup and of the millions of dollars that shareholders have been bilked out of . Cytori has been the private piggy bank of management for 15 years ,they will continue to draw salaries, perks, options etc, until the golden goose is dead, The goose is very ill
Not here to pump, or to blow smoke up people's a $ $ like you and so many others. people who post have agendas I don't just to post the facts and truth. Sorry if you can't handle it.
GLTY . Your time would be better spent writing to management
I could give you dozens of reason and you are obviously new and have not been involved as long as I. I'll keep it to a few
Management has zero credibility, they have promised to address the #1 issue which they have yet to do which is the balance sheet,
Cellution 2 machine delayed
No revenue from Japan as promised
No orders from KT or revenues from China as promised after approval of law there which has happened
Barda has not delivered $'s as promised after approval to move forward
No use of technology in Europe where it has been approved for years
Manipulation by the shorts
No meaningful insider buying. If management doesn't believe in themselves why should investors
Shall, I continue ?
You answered your own question. There reputations stink and investors who have followed the anaysts are in the toilet. They are just part of the scam. I can't believe I have let myself be Calhouned again. This whole thing just makes me sick and actually thinking that this wiuld turn around is just insanity. Shame on me.
Again, You clearly do not understand the new marketing strategy of Cytori. It is no longer about selling consumables or machines as per the FDA Cytori will be selling the stem cells. This is how the FDA can regulate in the USA. Outside USA yes they will sell machines and consumables perhaps one day when cellution 2 is ready for market.
Cytori is moving ADRCs (Adipose-derived regenerative cells) closer to entering the clinic for thermal burn and radiation exposure with data presented at the 2015 meeting of the American Burn Association this week in Chicago. Cytori made two presentations.
The first showed preclinical evidence of accelerated wound healing with increased blood vessel density, collagen deposition and epithelialization (skin) using large animal models of thermal burns and radiation exposure.
This is the first large animal model that reflects the clinical situation of patients exposed to thermal and radiation injury. (ABSTRACT LINK)
The second presentation showed improved dermal regeneration, vascularization and structural organization of thermal burn injuries over control when ADRCs were seeded onto a collagen scaffold. (ABSTRACT LINK)
Conclusion: These data put Cytori closer to the clinic. If the company can get to the clinic, the BARDA contract is structured to add $8M of funding for the first trial, beyond which there are options for additional work in thermal burns complicated by radiation exposure; combined value of $68M. ADRCs are also being evaluated in a pivotal study for scleroderma.
Thermal Burns and BARDA. The BARDA contract is worth up to $106M in non-dilutive capital. The contract with BARDA is now worth $14.1M with the additional $2M added on December 19, 2014. This funds Cytori through pilot studies and planning of an initial clinical trial for thermal burns. If successful in preclinical studies, and with approval of an IDE, another $8M will be added onto the contract to fund a clinical trial. The company anticipates completing the trial following the release of the next-generation Celution system in 2015. The contract also has two options valued at $45M and $23M that could fund a pivotal trial and additional work in thermal burns complicated by radiation exposure. The path through clinical development for ADRCs in thermal burns has the potential to be more rapid than we previously thought as we have now seen the ADRC Celution System given a pathway to approval that includes running only a modest-sized phase II/III pivotal clinical trial in scleroderma.
Adipose-Derived Stem and Regenerative Cells; is fat good? ADRCs, as the name implies, are derived from fat. A key publication describing how ADRCs are characterized after being isolated from adipose tissue with the Celution System was published in 2008 (Lin et al.'Characterization of adipose tissue-derived cells isolated with the celution system', Cytotherapy (2008), Vol. 10, Nov 4). Yes, fat tissue has cells with broad regenerative medicine potential. In fact, adipose tissue is the richest known source of adult stem cells. When you compare that adipose tissue containing 2-5% regenerative cells (ADRCs) to 0.0004% regenerative cells in the same person’s bone marrow, it’s a significant difference. Cytori isolates ADRCs using the ‘Celution System’ which is an automated process that can deliver autologous, point-of-care regenerative cell therapy with minimal handling and manipulation, the latter contributing to low cost of goods sold for the company. Additional indications include thermal burns, scleroderma, stress urinary incontinence, osteoarthritis and acute myocardial infarction.
Valuation. We assume Cytori will be successful in Scleroderma and multiple other indications utilizing ADRCs (thermal burns, stress urinary incontinence, and osteoarthritis. We apply a 25% risk cut to our therapeutic model and a 30% discount to financial models for FCFF, discounted EPS, and SOP to arrive at a $6.00 PT.
No it is not but actually monetizing it and getting partners seems to be a hrdle they have yet to be able to overcome. You can't eat potential.